Related Experiment Video
Updated: Apr 12, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.9K
How I treat Waldenström macroglobulinemia
1Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA.
Blood
|May 24, 2015
Summary
Waldenström macroglobulinemia (WM) is a rare B-cell cancer. Key mutations MYD88 and CXCR4 influence its presentation and survival, guiding personalized treatment strategies for this rare disease.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Waldenström macroglobulinemia (WM) is a lymphoplasmacytic B-cell neoplasm characterized by clonal IgM-secreting cells.
- MYD88 and CXCR4 mutations are prevalent in WM, affecting disease course and patient outcomes.
Observation:
- Familial predisposition is noted in WM.
- Treatment decisions are guided by disease-related symptoms and complications such as anemia, cytopenias, hyperviscosity, and neuropathy.
- Plasmapheresis is crucial for symptomatic hyperviscosity and before rituximab in high IgM patients.
Findings:
- Frontline therapies include rituximab, alkylators, proteasome inhibitors, nucleoside analogs, and ibrutinib.
- Salvage options encompass alternative regimens, ibrutinib, everolimus, and stem cell transplantation.
- Investigational therapies target MYD88, CXCR4, BCL2, CD27/CD70, and utilize novel agents and CAR T-cell therapy.
Implications:
- Understanding the role of MYD88 and CXCR4 mutations allows for tailored treatment approaches in WM.
- Personalized therapeutic strategies are essential for optimizing outcomes in WM patients.
- Ongoing research into novel agents and targeted therapies promises improved treatment options for Waldenström macroglobulinemia.
